| Schedule of Segment Information |
Selected financial information for the Company’s
operating segments is as follows:
| |
|
Three Months Ended March 31, |
|
| |
|
2019 |
|
|
2018 |
|
| Net revenues – External |
|
|
|
|
|
|
|
|
| Hospital Operations |
|
$ |
5,105,265 |
|
|
$ |
1,556,075 |
|
| Clinical Laboratory Operations |
|
|
85,385 |
|
|
|
45,586 |
|
| |
|
$ |
5,190,650 |
|
|
$ |
1,601,661 |
|
| Net loss from continuing operations before income taxes |
|
|
|
|
|
|
|
|
| Hospital Operations |
|
$ |
(3,175,107 |
) |
|
$ |
(1,472,600 |
) |
| Clinical Laboratory Operations |
|
|
(225,530 |
) |
|
|
(756,083 |
) |
| Corporate |
|
|
(1,072,835 |
) |
|
|
(1,483,341 |
) |
| Other income (expense) ,net |
|
|
(8,459,323 |
) |
|
|
(143,074,277 |
) |
| |
|
$ |
(12,932,795 |
) |
|
$ |
(146,786,301 |
) |
| Depreciation and amortization |
|
|
|
|
|
|
|
|
| Hospital Operations |
|
$ |
173,776 |
|
|
$ |
37,728 |
|
| Clinical Laboratory Operations |
|
|
49,662 |
|
|
|
295,474 |
|
| Corporate |
|
|
148 |
|
|
|
313 |
|
| |
|
$ |
223,586 |
|
|
$ |
333,515 |
|
| Capital expenditures |
|
|
|
|
|
|
|
|
| Hospital Operations |
|
$ |
42,317 |
|
|
$ |
301 |
|
| Clinical Laboratory Operations |
|
|
- |
|
|
|
- |
|
| |
|
$ |
42,317 |
|
|
$ |
301 |
|
| |
|
As of |
|
| |
|
March 31, 2019 |
|
|
December 31, 2018 |
|
| Total assets |
|
|
|
|
|
|
|
|
| Hospital Operations |
|
$ |
14,856,310 |
|
|
$ |
13,568,933 |
|
| Clinical Laboratory Operations |
|
|
462,354 |
|
|
|
271,426 |
|
| Corporate |
|
|
2,588,391 |
|
|
|
2,707,416 |
|
| Assets of AMSG and HTS classified as held for sale |
|
|
172,539 |
|
|
|
152,171 |
|
| Eliminations |
|
|
(2,466,859 |
) |
|
|
(2,500,646 |
) |
| |
|
$ |
15,612,735 |
|
|
$ |
14,199,300 |
|
|